

Notice of Allowability	Application No.	Applicant(s)
	09/716,536	LEE ET AL.
	Examiner	Art Unit
	Michael Pak	1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--
 claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included
 rewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS
 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative
 of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

This communication is responsive to 1-4-2004.

The allowed claim(s) is/are 32-41.

The drawings filed on _____ are accepted by the Examiner.

Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the
 International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements
 noted below. Failure to timely comply will result in ABANDONMENT of this application.
HIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF
 INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 1) hereto or 2) to Paper No./Mail Date _____
 (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of
 Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of
 each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the
 attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

Notice of References Cited (PTO-892)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statements (PTO-1449 or PTO/SB/08),
 Paper No./Mail Date _____

Examiner's Comment Regarding Requirement for Deposit
 of Biological Material

5. Notice of Informal Patent Application (PTO-152)

6. Interview Summary (PTO-413),
 Paper No./Mail Date _____

7. Examiner's Amendment/Comment

8. Examiner's Statement of Reasons for Allowance

9. Other _____.

Michael D. PAK
MICHAEL PAK
PRIMARY EXAMINER

EXAMINER'S AMENDMENT

1. Amendment filed 4 January 2004 has been entered.
2. The title has been amended to "*DNA encoding TRIP.*"
3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Veronica Mallon on 18 March 2004.

The application has been amended as follows:

Cancel claims 10-15.

Add the following claims:

-- 32. (new) An isolated nucleic acid molecule comprising a DNA sequence which encodes Tumor Necrosis Factor Receptor Associated Factor Interacting Protein (TRIP), wherein said DNA hybridizes to SEQ ID NO:7 (human TRIP DNA) or SEQ ID NO:8 (mouse TRIP DNA) sequence under standard hybridization condition, wherein the standard hybridization condition comprises both hybridization and wash condition at 5x SSC at 65° C, wherein said TRIP regulates TRAF-2 mediated NF-κB activation.

33. (new) The isolated nucleic acid molecule of claim 32, wherein said TRIP comprises SEQ ID NO: 1, SEQ ID NO: 2, or fragment thereof wherein the fragment regulates TRAF-2 mediated NF- κB activation.

34. (new) The isolated nucleic acid molecule of claim 33, wherein said fragment comprise SEQ ID NO: 3, 4, 5, or 6.
35. (new) An isolated nucleic acid molecule that encodes any one of SEQ ID NO: 1-6.
36. (new) The DNA sequence of any one of claims 32-34, wherein said DNA sequence is operatively linked to an expression control sequence.
37. (new) A probe capable of screening for TRIP in alternate species comprising the DNA sequence of any one of claims 32-34.
38. (new) An isolated recombinant DNA molecule comprising the DNA sequence of any one of claims 32-34.
39. (new) An isolated vector comprising the recombinant DNA molecule of any one of claims 32-38.
40. (new) A unicellular host transformed with the vector of claim 39.
41. (new) An isolated nucleic acid molecule comprising the DNA sequence that is fully complementary to the DNA sequence of any one of claims 32-35. –

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak whose telephone number is 571-272-0879. The examiner can normally be reached on 8:30 am - 2:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 571-272-0871. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9306 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-0507.

Michael D. Pak
Michael Pak
Primary Examiner
Art Unit 1646
March 20, 2004